<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05039450</url>
  </required_header>
  <id_info>
    <org_study_id>AK-US-001-0103</org_study_id>
    <nct_id>NCT05039450</nct_id>
  </id_info>
  <brief_title>A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)</brief_title>
  <official_title>A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akero Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akero Therapeutics, Inc</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind,&#xD;
      placebo-controlled study in cirrhotic subjects with biopsy-proven F4 compensated NASH.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in fibrosis regression with no worsening steatohepatitis assessed by NASH CRN system</measure>
    <time_frame>Week 36</time_frame>
    <description>Proportion of subjects who achieve ≥ 1 stage improvement in fibrosis (based on NASH CRN fibrosis score) and no worsening of steatohepatitis at Week 36.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resolution of NASH with no worsening of fibrosis assessed by the NASH CRN system</measure>
    <time_frame>Week 36, Week 96</time_frame>
    <description>Proportion of subjects who achieve NASH resolution (defined as a NAS of 0-1 for inflammation and 0 for ballooning) as determined by the NASH CRN criteria at Week 36 and Week 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fibrosis regression in subjects with no worsening of steatohepatitis assessed by the NASH CRN system</measure>
    <time_frame>Week 96</time_frame>
    <description>Proportion of subjects who achieve ≥ 1 stage improvement in fibrosis (based on NASH CRN fibrosis score) and no worsening of steatohepatitis at Week 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fibrosis regression in subjects with no worsening of steatohepatitis assessed by the NASH CRN system</measure>
    <time_frame>Week 36, Week 96</time_frame>
    <description>Proportion of subjects who achieve ≥ 1 stage improvement in fibrosis (based on NASH CRN fibrosis score) at Week 36 and Week 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in non-invasive markers of fibrosis</measure>
    <time_frame>Week 36, Week 48, Week 72, Week 96</time_frame>
    <description>Change from baseline in ELF score, Pro-C3 (ug/L),and liver stiffness assessed by liver elastography (kPa, CAP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in lipoproteins</measure>
    <time_frame>Week 36, Week 48, Week 72, Week 96</time_frame>
    <description>Change from baseline in Triglycerides (mg/dL), total cholesterol (mg/dL), HDL-C (mg/dL), non-HDL-C (mg/dL), and LDL-C (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of markers in insulin sensitivity and glycemic control</measure>
    <time_frame>Week 36, Week 48, Week 72, Week 96</time_frame>
    <description>Change from baseline in HbA1c (%), C-peptide (ug/L), adiponectin (mg/L), insulin (mIU/L), and HOMA-IR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body weight</measure>
    <time_frame>Week 36, Week 48, Week 96</time_frame>
    <description>Change from baseline in body weight (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the immunogenicity of EFX</measure>
    <time_frame>Through Week 96</time_frame>
    <description>Detect and measure ADA, including NAb, against EFX</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of EFX</measure>
    <time_frame>Through Week 96</time_frame>
    <description>Safety and tolerability will be assessed through the reporting of AEs, clinical laboratory tests, ECGs, ultrasounds, vital sign assessments, and concomitant medication usage</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>EFX 28 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>EFX 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EFX</intervention_name>
    <description>Investigational drug, Efruxifermin</description>
    <arm_group_label>EFX 28 mg</arm_group_label>
    <arm_group_label>EFX 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and non-pregnant, non-lactating females between 18-75 years of age inclusive,&#xD;
             based on the date of signing informed consent.&#xD;
&#xD;
          -  Previous history or presence of Type 2 diabetes or 2 out of 4 components of metabolic&#xD;
             syndrome (obesity, dyslipidemia, elevated blood pressure, elevated fasting glucose).&#xD;
&#xD;
          -  Biopsy-proven compensated cirrhosis due to NASH.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Weight loss &gt; 10% in the 3 months prior to screening until randomization or from the&#xD;
             time of collection of the liver biopsy used to assess subject eligibility until&#xD;
             randomization, whichever is longer.&#xD;
&#xD;
          -  Type 1 diabetes or uncontrolled Type 2 diabetes&#xD;
&#xD;
        Other inclusion and exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Akero Study Director</last_name>
    <phone>650-487-6488</phone>
    <email>SymmetryStudy@akerotx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 0106</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 0104</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 0210</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <zip>72117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 0214</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 0102</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 0128</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 0130</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>September 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

